TFR - a new treatment goal of CP-CML patients?
Dr Delphine Réa, Centre-Hospitalo-Universitaire Saint-Louis, Paris, France 

• Lessons from clinical trials: TKI discontinuation in CP-CML is feasible
• Deep-molecular responses: definitions
• Clinical practice: patient case
• Deep-molecular responses during 1st line TKI treatment
• TKI discontinuation in CP-CML: transition from trials to standard practice
• TKI withdrawal syndrome during the treatment-free phase
• Recommendations for standard practice: definitions and management of relapses
• Conclusion 1: Evolving treatment goals
• Conclusion 2: TKI discontinuation in standard practice